Eisai Co., Ltd.
Eisai Co., Ltd.
Explore linked clinical trials.15 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants | Hepatic Impairment | Recruiting | Phase 1 | 2026-09-17 | NCT04271488 | |
| Study of E7389 Liposomal Formulation in Participants With Solid Tumor | Solid Tumor | Active, not recruiting | Phase 1 | 2026-08-27 | NCT03207672 | |
| A Study of E6742 in Participants With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-08-21 | NCT07515014 | |
| A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, visual epilepsy | Recruiting | Not stated | 2026-07-01 | NCT06657378 | |
| Lemborexant in Delayed Sleep Phase Syndrome | Chronobiology Disorders, Dyssomnias, Occupational Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, circadian rhythm sleep disorder, circadian rhythm sleep disorder, delayed sleep phase type, disease, nervous system disorder, psychiatric disorder, sleep-wake disorder, syndromic disease | Recruiting | Phase 4 | 2026-06-05 | NCT06874855 | |
| A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Recruiting | Not stated | 2026-02-27 | NCT06793709 | |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, colonic disorder, colorectal neoplasm, connective tissue neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, digestive system neuroendocrine neoplasm, endocrine system disorder, epithelial neoplasm, fibroma, hepatocellular carcinoma, intestinal disorder, liver disorder, malignant endocrine neoplasm, neoplasm, rectal disorder | Active, not recruiting | Phase 1 | 2026-02-27 | NCT03833700 | |
| A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT04078295 | |
| A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-01-23 | NCT06322667 | |
| A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-01-02 | NCT05228158 | |
| Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Not stated | 2025-10-03 | NCT05153941 | |
| NCCH2006/MK010 Trial (FORTUNE Trial) | Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Limb Deformities, Congenital, Musculoskeletal Abnormalities, bone disorder, craniosynostosis, dysostosis, musculoskeletal system disorder, syndactyly, synostosis | Recruiting | Phase 2 | 2025-10-03 | NCT04962867 | |
| Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-09-25 | NCT02562118 | |
| Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-07-25 | NCT05181033 | |
| Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study) | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 4 | 2025-04-06 | NCT06913907 |